Cassava Sciences Reports Top-Line Results Of Two-Year Clinical Safety Study Of Simufilam, Investigational Oral Drug For Treatment Of Alzheimer's Disease
Cassava Sciences Reports Top-Line Results Of Two-Year Clinical Safety Study Of Simufilam, Investigational Oral Drug For Treatment Of Alzheimer's Disease
Cassava Sciences報告了爲期兩年的Simufilam臨床安全性研究的主要結果，Simufilam是治療阿爾茨海默氏病的在研口服藥物
-
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer's Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.
-
Mild Alzheimer's Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.
- Oral Simufilam Safe, Well-Tolerated.
- 在基線至第24個月持續接受候選藥物Simufilam治療的一組輕度阿爾茨海默氏症患者中，ADAS-Cog分數保持穩定。
- 非連續接受Simufilam治療的輕度阿爾茨海默氏症患者在ADAS-Cog上平均下降了1分，基線爲第24個月。
- 口服 Simufilam 安全，耐受性良好。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。